A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Gossamer Bio, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 98,900 shares of GOSS stock, worth $99,889. This represents 0.0% of its overall portfolio holdings.

Number of Shares
98,900
Previous 110,400 10.42%
Holding current value
$99,889
Previous $100,000 16.0%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$0.8 - $1.51 $1.81 Million - $3.42 Million
-2,265,506 Reduced 36.9%
3,874,726 $4.57 Million
Q4 2023

Feb 14, 2024

SELL
$0.48 - $1.08 $13,397 - $30,143
-27,911 Reduced 0.45%
6,140,232 $5.59 Million
Q3 2023

Nov 14, 2023

BUY
$0.78 - $1.82 $3.7 Million - $8.63 Million
4,741,674 Added 332.41%
6,168,143 $5.12 Million
Q2 2023

Aug 14, 2023

SELL
$0.98 - $1.53 $1.34 Million - $2.09 Million
-1,368,248 Reduced 48.96%
1,426,469 $1.71 Million
Q1 2023

May 15, 2023

BUY
$0.96 - $2.92 $2.68 Million - $8.16 Million
2,794,717 New
2,794,717 $3.52 Million
Q3 2022

Nov 14, 2022

SELL
$7.21 - $14.88 $11.2 Million - $23.1 Million
-1,551,585 Reduced 67.97%
731,264 $8.76 Million
Q2 2022

Aug 15, 2022

BUY
$5.97 - $9.97 $827,071 - $1.38 Million
138,538 Added 6.46%
2,282,849 $19.1 Million
Q1 2022

May 16, 2022

BUY
$8.44 - $12.49 $2.27 Million - $3.35 Million
268,560 Added 14.32%
2,144,311 $18.6 Million
Q4 2021

Feb 14, 2022

BUY
$10.12 - $14.07 $2.91 Million - $4.05 Million
287,800 Added 18.12%
1,875,751 $21.2 Million
Q3 2021

Nov 15, 2021

BUY
$7.25 - $13.23 $11.4 Million - $20.8 Million
1,572,150 Added 9949.69%
1,587,951 $20 Million
Q2 2021

Aug 16, 2021

SELL
$8.0 - $9.75 $4.52 Million - $5.51 Million
-564,995 Reduced 97.28%
15,801 $128,000
Q1 2021

May 17, 2021

SELL
$8.63 - $10.94 $1.64 Million - $2.08 Million
-189,962 Reduced 24.65%
580,796 $5.37 Million
Q4 2020

Feb 16, 2021

BUY
$8.3 - $13.59 $5.74 Million - $9.39 Million
691,286 Added 869.85%
770,758 $7.45 Million
Q3 2020

Nov 16, 2020

BUY
$11.3 - $14.75 $376,131 - $490,968
33,286 Added 72.07%
79,472 $986,000
Q2 2020

Aug 14, 2020

SELL
$9.52 - $15.98 $2.55 Million - $4.29 Million
-268,266 Reduced 85.31%
46,186 $600,000
Q1 2020

May 15, 2020

BUY
$8.0 - $15.48 $2.18 Million - $4.22 Million
272,828 Added 655.46%
314,452 $3.19 Million
Q4 2019

Feb 14, 2020

SELL
$14.82 - $26.79 $13.1 Million - $23.6 Million
-881,320 Reduced 95.49%
41,624 $650,000
Q3 2019

Nov 14, 2019

SELL
$16.02 - $22.47 $63,727 - $89,385
-3,978 Reduced 0.43%
922,944 $15.5 Million
Q2 2019

Aug 14, 2019

SELL
$16.12 - $22.89 $735,894 - $1.04 Million
-45,651 Reduced 4.69%
926,922 $20.6 Million
Q1 2019

May 15, 2019

BUY
$17.58 - $23.97 $17.1 Million - $23.3 Million
972,573 New
972,573 $0

Others Institutions Holding GOSS

About Gossamer Bio, Inc.


  • Ticker GOSS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,954,000
  • Market Cap $94.9M
  • Description
  • Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...
More about GOSS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.